SNRPD Human

Small Nuclear Ribonucleoprotein Polypeptide D1, D2, D3 Human Recombinant
Shipped with Ice Packs
In Stock

Description

Introduction to SNRPD Human

SNRPD Human is a heterotrimeric protein complex produced recombinantly in Sf9 insect cells. Each subunit (SNRPD1, SNRPD2, SNRPD3) is fused with a 6xHis tag for purification and exhibits molecular weights of approximately 14–16 kDa . It is widely used in autoimmune disease research and cancer studies due to its role in spliceosome assembly and RNA processing .

Diagnostic and Mechanistic Studies

  • Autoimmune Diseases: SNRPD Human binds anti-Sm antibodies in systemic lupus erythematosus (SLE) sera, serving as a diagnostic antigen .

  • Western Blot/ELISA: Validated for detecting SNRPD1 in human cell lines (HEK-293, HL-60) .

Functional Pathways

PathwayRole of SNRPD1Clinical Impact
Spliceosome AssemblyScaffolds snRNP interactions via RNAMutations disrupt mRNA splicing
Cell CycleEnriched in mitotic nuclear divisionDrives tumor proliferation
DNA RepairAffects mismatch repair mechanismsAssociated with chemotherapy resistance

Therapeutic Targeting

  • miR-100 Interaction: SNRPD1 is a direct target of miR-100, which is downregulated in HCC (r = -0.49, p = 3.59e-23) .

  • Drug Resistance: SNRPD1 amplification in 7% of HCC patients correlates with shorter survival (p = 0.034) .

Product Specs

Description
SNRPD Human Recombinant, produced in SF9 insect cells, is a mixed protein complex comprising the SNRPD1 (14,306 Dalton), SNRPD2 (14,773 Dalton), and SNRPD3 (14,739 Dalton) proteins. Each protein (SNRPD1, SNRPD2, and SNRPD3) is individually tagged with a 6xHis tag at the N-terminus and purified using proprietary chromatographic techniques.
Physical Appearance
Clear, sterile-filtered solution.
Formulation
SNRPD is supplied in a 20mM HEPES buffer with a pH of 7.6, 250mM NaCl, and 20% glycerol.
Stability
For short-term storage (2-4 weeks), store at 4°C. For long-term storage, freeze at -20°C. Repeated freeze-thaw cycles should be avoided.
Purity
Purity exceeds 80% as determined by SDS-PAGE.
Coating Concentration
The recommended coating concentration is 0.4-0.8 µg/ml, which may vary depending on the ELISA plate type and coating buffer used. Suitable for functional group labeling.
Applications
Western blot applications include: (a) Use with anti-Sm positive patient sera. (b) Use with monoclonal anti-hexa-His-tag antibody.
Immunological Functions
The immunological functions are: 1. Binding to IgG-type human auto-antibodies. 2. Use as a standard in ELISA tests (checkerboard analysis of positive and negative sera panels).
Source
Sf9 insect cells.

Q&A

What is SNRPD1 and what is its functional role in human cellular processes?

SNRPD1 (Small Nuclear Ribonucleoprotein D1 Polypeptide) is a protein-coding gene that encodes a small nuclear ribonucleoprotein belonging to the SNRNP core protein family. The protein functions as a charged protein scaffold that promotes SNRNP assembly and strengthens SNRNP-SNRNP interactions through nonspecific electrostatic contacts with RNA . It is a critical component of the spliceosome machinery, particularly the U5 snRNP complex that participates in pre-mRNA splicing.

Methodological approach to study function: Researchers should employ a combination of structural biology techniques (cryo-EM, X-ray crystallography) alongside functional assays (in vitro splicing assays, RNP assembly assays) to fully characterize SNRPD1's role in spliceosomal dynamics.

How is SNRPD1 organized structurally and what domains mediate its functions?

SNRPD1 contains specific structural domains that facilitate its incorporation into snRNP complexes:

  • RNA-binding domains that interact with U5 snRNA

  • Protein-protein interaction regions that enable assembly into the snRNP core

  • Structural motifs that contribute to the architecture of the spliceosome

When designing experiments to investigate SNRPD1 structure-function relationships, researchers should consider domain-specific mutagenesis followed by assembly and activity assays to pinpoint critical regions.

What is known about SNRPD1 expression patterns across human tissues?

SNRPD1 shows differential expression patterns across various human tissues. According to the Allen Brain Atlas data, expression levels vary significantly in different brain regions . A methodological approach to studying tissue-specific expression would involve:

  • RNA-seq analysis across tissue panels

  • Quantitative RT-PCR for targeted validation

  • Western blot analysis with tissue-specific lysates

  • Immunohistochemistry for spatial localization

  • Single-cell sequencing for cell-type specific expression profiling

What are optimal protocols for isolating SNRPD1-containing snRNP complexes?

Isolation of functional SNRPD1-containing complexes requires careful experimental design:

  • Immunoprecipitation approach:

    • Use antibodies against SNRPD1 or other U5 snRNP components

    • Employ gentle lysis conditions to maintain complex integrity

    • Consider crosslinking to capture transient interactions

  • Density gradient approach:

    • Use glycerol gradients (10-30%) to separate different snRNP complexes

    • Monitor sedimentation profiles (20S U5 snRNP vs. tri-snRNP)

    • Combine with western blot analysis to track specific components

  • RNA-based purification:

    • Design antisense oligonucleotides complementary to U5 snRNA

    • Couple to solid supports for affinity purification

    • Elute under native conditions to maintain structural integrity

The experimental design should include appropriate controls to account for non-specific binding and should verify complex integrity through functional assays.

How should researchers design experiments to study SNRPD1 function in splicing?

When designing experiments to study SNRPD1's role in splicing:

Experimental ApproachKey ControlsReadout MethodsAnalysis Considerations
RNAi-mediated knockdownNon-targeting siRNA, rescue with RNAi-resistant constructRT-PCR of target transcripts, RNA-seqAccount for potential off-target effects
CRISPR-Cas9 genome editingWild-type cells, multiple guide RNAsSplicing-sensitive microarrays, RNA-seqConsider compensatory mechanisms
In vitro splicing assaysMock-depleted extracts, add-back experimentsGel electrophoresis, quantitative RT-PCRControl for extract variability
Protein-RNA crosslinkingNo-crosslink controls, competition assaysMass spectrometry, RNA sequencingBackground subtraction algorithms

Researchers should employ a factorial design when studying multiple variables and control for extraneous variables through randomization, constancy, and counterbalancing as described in experimental design principles .

What techniques are most effective for structural characterization of SNRPD1 in snRNP complexes?

For structural characterization of SNRPD1 within snRNP complexes:

  • Cryo-electron microscopy:

    • Recent advances have enabled high-resolution (3.1 Å) structures of the 20S U5 snRNP

    • Model statistics from published structures provide benchmarks:

ParameterFull ComplexCore Domain
Model resolution (Å)3.23.2
FSC threshold0.50.5
Model resolution range (Å)2.7–152.7–5
Non-hydrogen atoms42,34128,634
Protein residues6,3943,316
MolProbity score2.162.21
Clashscore11.614.3
  • Complementary approaches:

    • Hydrogen/deuterium exchange mass spectrometry for dynamics

    • Crosslinking mass spectrometry for interface mapping

    • NMR for local structural elements

How does SNRPD1 participate in the assembly pathway of the U5 snRNP complex?

SNRPD1 plays a critical role in U5 snRNP assembly through a stepwise process:

  • Initial incorporation into the U5 snRNP precursor complex

  • Participation in the 20S U5 snRNP formation, which contains 17 protein subunits and acts as a precursor to the tri-snRNP complex

  • Interaction with assembly factors like CD2BP2, which is present in 20S U5 snRNP but absent from mature tri-snRNP

Research methodology should include:

  • Pulse-chase experiments with tagged components

  • Time-resolved structure determination

  • In vitro reconstitution assays

  • Assembly intermediates captured through modified purification strategies

The recent cryo-EM structure of the human 20S U5 snRNP provides evidence that CD2BP2 facilitates the recruitment of other components critical for tri-snRNP formation and may function as a two-layered buffer blocking certain protein-protein interactions until the appropriate assembly stage .

What is the significance of SNRPD1 interactions with other spliceosomal proteins?

SNRPD1 interactions should be studied through:

  • Protein-protein interaction mapping:

    • Yeast two-hybrid screening

    • Proximity labeling (BioID, APEX)

    • Co-immunoprecipitation coupled with mass spectrometry

  • Functional validation:

    • Mutational analysis of interaction interfaces

    • Competition assays with peptide mimics

    • Structure-guided interface disruption

Researchers should focus on the mutually exclusive interfaces utilized during tri-snRNP assembly, as revealed by structural studies . For example, CD2BP2 occupies surfaces on PRP8 that are later bound by other factors during spliceosome assembly and activation.

How do alterations in SNRPD1 impact global splicing patterns and cellular phenotypes?

Methodological approaches to assess SNRPD1's impact on splicing include:

  • Transcriptome analysis:

    • RNA-seq with specific computational pipelines for alternative splicing

    • RT-PCR validation of specific splicing events

    • Nascent RNA sequencing to capture co-transcriptional splicing events

  • Phenotypic assays:

    • Cell viability and proliferation in response to SNRPD1 modulation

    • Cell cycle analysis to identify stage-specific effects

    • Stress response characterization

  • Rescue experiments:

    • Structure-guided mutations to test specific interaction hypotheses

    • Domain swaps to identify functional regions

    • Expression of splice variants to assess isoform-specific functions

What bioinformatic approaches are most suitable for analyzing SNRPD1-dependent splicing events?

When analyzing SNRPD1-dependent splicing:

  • Differential splicing analysis:

    • rMATS, MAJIQ, or LeafCutter for junction-centric analysis

    • DEXSeq for exon usage quantification

    • SUPPA2 for alternative splicing event detection

  • Data visualization:

    • Sashimi plots for splice junction visualization

    • Heatmaps for clustering of splicing patterns

    • Volcano plots for significance assessment

  • Motif analysis:

    • Identify sequence motifs enriched near SNRPD1-dependent splicing events

    • Correlate with RNA-binding protein binding sites

    • Structural motif prediction around affected splice sites

  • Network analysis:

    • Build splicing regulatory networks using co-expression data

    • Identify hubs and bottlenecks in splicing regulation

    • Perform pathway enrichment on affected transcripts

How should contradictory findings about SNRPD1 function be reconciled in research?

To reconcile contradictory findings:

  • Methodological assessment:

    • Evaluate differences in experimental systems (cell types, extract preparation)

    • Compare antibody specificities and validation methods

    • Assess statistical power and reproducibility

  • Context-dependent analysis:

    • Consider cell type-specific functions

    • Evaluate impacts of cellular stress and environmental conditions

    • Account for potential redundancy with other splicing factors

  • Integration of multiple data types:

    • Combine genomic, transcriptomic, and proteomic data

    • Use statistical methods for meta-analysis

    • Employ Bayesian approaches to weight conflicting evidence

Researchers should follow rigorous experimental design principles including randomization, appropriate controls, and blinding where applicable to minimize bias in interpretation .

What are promising methodological innovations for studying SNRPD1 dynamics in living cells?

Emerging methodologies include:

  • Live-cell imaging:

    • CRISPR-based tagging of endogenous SNRPD1

    • Optogenetic control of SNRPD1 interactions

    • Super-resolution microscopy of splicing bodies

  • Single-molecule approaches:

    • smFRET to monitor conformational changes

    • Single-particle tracking to follow assembly/disassembly

    • Zero-mode waveguides for single-molecule splicing

  • Systems biology approaches:

    • Multi-omics integration (transcriptome, proteome, interactome)

    • Mathematical modeling of assembly pathways

    • Machine learning for splicing outcome prediction

Researchers should design experiments with appropriate controls and validation steps, while considering the technical limitations of each approach.

Product Science Overview

Introduction

Small nuclear ribonucleoproteins (snRNPs) are essential components of the spliceosome, the complex responsible for pre-mRNA splicing in eukaryotic cells. Among these, the D1, D2, and D3 polypeptides play crucial roles in the assembly and function of snRNPs. This article delves into the background, structure, and significance of these polypeptides, particularly focusing on their human recombinant forms.

Structure and Function

The small nuclear ribonucleoprotein polypeptides D1, D2, and D3 are part of the core protein family of snRNPs. These proteins are integral to the formation of the spliceosomal U1, U2, U4, and U5 snRNPs, which are the building blocks of the spliceosome .

  • D1 Polypeptide: Encoded by the SNRPD1 gene, the D1 polypeptide acts as a charged protein scaffold, promoting snRNP assembly and strengthening snRNP-snRNP interactions through nonspecific electrostatic contacts with RNA . It is involved in the splicing of U12-type introns in pre-mRNAs .
  • D2 Polypeptide: Encoded by the SNRPD2 gene, the D2 polypeptide is required for pre-mRNA splicing and snRNP biogenesis . It interacts with other snRNP components to facilitate the assembly and function of the spliceosome.
  • D3 Polypeptide: Encoded by the SNRPD3 gene, the D3 polypeptide shares structural similarities with D1 and D2 and is involved in the same processes . It plays a role in the formation of the snRNP core and the overall stability of the spliceosome.
Recombinant Forms

Human recombinant forms of these polypeptides are produced using recombinant DNA technology, which involves inserting the gene encoding the polypeptide into a suitable expression system, such as bacteria or yeast. This allows for the production of large quantities of the protein, which can be purified and used for various research and therapeutic purposes.

Significance in Disease

Mutations or dysregulation of the genes encoding these polypeptides have been associated with various diseases, including systemic lupus erythematosus and other autoimmune disorders . Understanding the structure and function of these polypeptides is crucial for developing targeted therapies for these conditions.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.